Neocor Therapeutics

Neocor Therapeutics is an early-stage biotech focused on pioneering gene therapies for cardiac regeneration and repair, targeting both ischemic and rare genetic heart diseases. The company employs a dual therapeutic approach aimed at promoting cardiomyocyte renewal and preventing cardiac fibrosis to preserve heart function. Led by a founding team with entrepreneurial and deep cardiovascular research expertise, and supported by a distinguished Scientific Advisory Board, Neocor is positioned in the high-need, high-value cardiology therapeutic space but remains at a pre-clinical, pre-revenue stage of development.

Novel gene therapy platform combining two complementary approaches: 1) Promoting cardiomyocyte renewal/regeneration to preserve cardiac performance, and 2) Preventing non-contractile cardiac fibrosis deposition to preserve contractility. Targets ischemic and rare genetic cardiac diseases.

Neocor operates in the competitive field of cardiac regeneration, facing rivals exploring cell therapies (e.g., stem cells), other gene therapies, RNA-based approaches, and small molecules from both large pharma and numerous biotech startups. Differentiation will depend on the efficacy and safety profile of its specific platform.